Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms REGAIN
- Sponsors Eli Lilly and Company
- 03 May 2023 Results of post hoc analysis (n=3348) assessing at population and individual patient levels, the sustained response of reduction in migraine headache days in patients with migraine treated with galcanezumab from two 6-month episodic migraine (EM; EVOLVE-1/EVOLVE-2), one 3-month chronic migraine (CM; REGAIN), and one 3-month treatment-resistant migraine (CONQUER) studies, published in the Headache.
- 12 Jun 2022 Results of post-hoc analysis of three studies (EVOLVE- 1 [NCT02614183] and EVOLVE- 2 [NCT02614196]) and CM (REGAIN [NCT02614261) assessing indirect cost savings with galcanezumab versus (vs.) placebo in episodic migraine (EM) and chronic migraine (CM), due to absence or productivity loss at school/work in the US, presented at the 64th Annual Scientific Meeting of the American Headache Society.
- 01 May 2022 Results assessing long-term safety and efficacy in the Current Medical Research and Opinion